Evogene Ltd. has announced a scientific collaboration with Professor Ehud [...]

FoRx Therapeutics has initiated a first-in-human clinical trial of FORX-428, [...]

Newron Pharmaceuticals has highlighted new preclinical findings published in Neuropsychopharmacology [...]

InflaRx has reported its Q2 2025 results and provided updates [...]

DEBRA Research, a non-profit focused on Epidermolysis bullosa (EB), has [...]

A genetically targeted approach to depression treatment has shown promising [...]

Revolo Biotherapeutics says it is accelerating plans to bring a [...]

James Anderson is the Chair of the INTREPID Alliance and the Executive Director of Global Health at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), a leading global organization representing pharmaceutical companies. In his role at IFPMA, James spearheads efforts to address critical global health challenges, including antimicrobial resistance, pandemic preparedness, and non-communicable diseases.

As debate continues over the cost and sustainability of GLP-1 [...]

Ethris has dosed the first patient in a Phase 2a [...]